Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E N Subong

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
The Journal of Urology|March 21, 1998
Differential nuclear matrix protein expression in prostate cancers: correlation with pathologic stageY Lakshmanan, E N Subong, A W Partin
The Journal of Urology|April 1, 1996
Standard versus age-specific prostate specific antigen reference ranges among men with clinically localized prostate cancer: A pathological analysisA W Partin, S R Criley, E N Subong, et al.
Urology|December 1, 1996
Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: influence of total PSA, prostate volume, and ageA W Partin, W J Catalona, P C Southwick, et al.
The Prostate|May 27, 1999
Monoclonal antibody to prostate cancer nuclear matrix protein (PRO:4-216) recognizes nucleophosmin/B23E N Subong, M J Shue, J I Epstein, et al.
The Prostate. Supplement|January 1, 1996
Clearance rate of serum-free and total PSA following radical retropubic prostatectomyA W Partin, S Piantadosi, E N Subong, et al.
Urology|December 31, 1997
Preliminary immunohistochemical characterization of a monoclonal antibody (PRO:4-216) prepared from human prostate cancer nuclear matrix proteinsA W Partin, J V Briggman, E N Subong, et al.
JAMA|May 14, 1997
Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional updateA W Partin, M W Kattan, E N Subong, et al.
The Journal of Urology|June 1, 1997
Prostate tissue composition and response to finasteride in men with symptomatic benign prostatic hyperplasiaL S Marks, A W Partin, G J Gormley, et al.
Urology|December 31, 1997
Molecular forms of prostate-specific antigen and human kallikrein 2 (hK2) in urine are not clinically useful for early detection and staging of prostate cancerJ Pannek, H G Rittenhouse, C L Evans, et al.
Urology|December 1, 1996
The role of free/total prostate-specific antigen ratio in the prediction of final pathologic stage for men with clinically localized prostate cancerJ Pannek, E N Subong, K A Jones, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
The Journal of Urology|March 21, 1998
Differential nuclear matrix protein expression in prostate cancers: correlation with pathologic stageY Lakshmanan, E N Subong, A W Partin
The Journal of Urology|April 1, 1996
Standard versus age-specific prostate specific antigen reference ranges among men with clinically localized prostate cancer: A pathological analysisA W Partin, S R Criley, E N Subong, et al.
Urology|December 1, 1996
Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: influence of total PSA, prostate volume, and ageA W Partin, W J Catalona, P C Southwick, et al.
The Prostate|May 27, 1999
Monoclonal antibody to prostate cancer nuclear matrix protein (PRO:4-216) recognizes nucleophosmin/B23E N Subong, M J Shue, J I Epstein, et al.
The Prostate. Supplement|January 1, 1996
Clearance rate of serum-free and total PSA following radical retropubic prostatectomyA W Partin, S Piantadosi, E N Subong, et al.
Urology|December 31, 1997
Preliminary immunohistochemical characterization of a monoclonal antibody (PRO:4-216) prepared from human prostate cancer nuclear matrix proteinsA W Partin, J V Briggman, E N Subong, et al.
JAMA|May 14, 1997
Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional updateA W Partin, M W Kattan, E N Subong, et al.
The Journal of Urology|June 1, 1997
Prostate tissue composition and response to finasteride in men with symptomatic benign prostatic hyperplasiaL S Marks, A W Partin, G J Gormley, et al.
Urology|December 31, 1997
Molecular forms of prostate-specific antigen and human kallikrein 2 (hK2) in urine are not clinically useful for early detection and staging of prostate cancerJ Pannek, H G Rittenhouse, C L Evans, et al.
Urology|December 1, 1996
The role of free/total prostate-specific antigen ratio in the prediction of final pathologic stage for men with clinically localized prostate cancerJ Pannek, E N Subong, K A Jones, et al.
Pageof 2